# EDGAR Filing Document

**Accession Number:** 0001576885
**File Stem:** 0001628280-26-022032
**Filing Date:** 2026-3
**Character Count:** 2540
**Document Hash:** c6fe6f25c79a07e8740eb5d73de3c3b4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-022032.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001628280-26-022032

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Acumen Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001576885
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 364108129
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1210-1220 WASHINGTON STREET
- **STREET 2:** SUITE 210
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02465
- **BUSINESS PHONE:** 617-344-4190

**MAIL ADDRESS:**
- **STREET 1:** 1210-1220 WASHINGTON STREET
- **STREET 2:** SUITE 210
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02465

**ACUMEN PHARMACEUTICALS, INC.**

1210-1220 Washington Street, Suite 210

Newton, Massachusetts 02465

(617) 344-4190

March 30, 2026

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

Attention: Tim Buchmiller

---

| | |
|:---|:---|
| RE: | &nbsp;&nbsp;&nbsp;Acumen Pharmaceuticals, Inc. |
| | &nbsp;&nbsp;&nbsp;Registration Statement on Form S-3 (File No. 333-294649) |
| | &nbsp;&nbsp;&nbsp;Request for Acceleration |

---

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Acumen Pharmaceuticals, Inc., a Delaware corporation (the "<u>Company</u>"), hereby respectfully requests that the effective date of its Registration Statement on Form S-3 (File No. 333-294649) (the "<u>Registration Statement</u>") be accelerated by the Securities and Exchange Commission so that it will be declared effective at 4:00 p.m. EST on April 1, 2026, or as soon as possible thereafter. The Company hereby authorizes Thomas Danielski of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

It would be appreciated if, as soon as the Registration Statement is declared effective, you would inform Thomas Danielski of Ropes & Gray LLP at <u>Thomas.Danielski@ropesgray.com</u> or (617) 235-4961.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **ACUMEN PHARMACEUTICALS, INC.** | **ACUMEN PHARMACEUTICALS, INC.** |
| By: | /s/ Daniel O'Connell |
|  | Daniel O'Connell |
|  | Chief Executive Officer |

---

<br>